IRWD Ironwood Pharmaceuticals Inc

Price (delayed)

$9.23

Market cap

$1.49B

P/E Ratio

13.78

Dividend/share

N/A

EPS

$0.67

Enterprise value

$1.59B

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Highlights

The company's equity has surged by 167% YoY
The quick ratio has surged by 98% year-on-year and by 17% since the previous quarter
IRWD's revenue is down by 9% YoY and by 2.4% QoQ
The EPS has declined by 6% since the previous quarter

Key stats

What are the main financial stats of IRWD
Market
Shares outstanding
160.96M
Market cap
$1.49B
Enterprise value
$1.59B
Valuations
Price to earnings (P/E)
13.78
Price to book (P/B)
23.59
Price to sales (P/S)
3.78
EV/EBIT
11.47
EV/EBITDA
11.18
EV/Sales
4.07
Earnings
Revenue
$389.52M
EBIT
$138.34M
EBITDA
$141.9M
Free cash flow
$166.99M
Per share
EPS
$0.67
Free cash flow per share
$1.05
Book value per share
$0.39
Revenue per share
$2.44
TBVPS
$3.51
Balance sheet
Total assets
$559.24M
Total liabilities
$496.6M
Debt
$465.79M
Equity
$62.64M
Working capital
$463.67M
Liquidity
Debt to equity
7.44
Current ratio
15.41
Quick ratio
15.85
Net debt/EBITDA
0.72
Margins
EBITDA margin
36.4%
Gross margin
99.2%
Net margin
27.3%
Operating margin
36.7%
Efficiency
Return on assets
22.4%
Return on equity
N/A
Return on invested capital
22.6%
Return on capital employed
26.2%
Return on sales
35.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IRWD stock price

How has the Ironwood Pharmaceuticals stock price performed over time
Intraday
2.1%
1 week
-3.25%
1 month
-9.42%
1 year
-16.62%
YTD
-18.96%
QTD
-18.96%

Financial performance

How have Ironwood Pharmaceuticals's revenue and profit performed over time
Revenue
$389.52M
Gross profit
$386.39M
Operating income
$142.94M
Net income
$106.18M
Gross margin
99.2%
Net margin
27.3%
IRWD's operating margin is up by 31% year-on-year and by 3.7% since the previous quarter
The operating income has increased by 19% YoY
IRWD's revenue is down by 9% YoY and by 2.4% QoQ
Ironwood Pharmaceuticals's gross profit has decreased by 5% YoY

Growth

What is Ironwood Pharmaceuticals's growth rate over time

Valuation

What is Ironwood Pharmaceuticals stock price valuation
P/E
13.78
P/B
23.59
P/S
3.78
EV/EBIT
11.47
EV/EBITDA
11.18
EV/Sales
4.07
IRWD's P/E is 15% below its last 4 quarters average of 16.3
The EPS has declined by 6% since the previous quarter
The company's equity has surged by 167% YoY
IRWD's P/S is 44% below its 5-year quarterly average of 6.7 and 3.1% below its last 4 quarters average of 3.9
IRWD's revenue is down by 9% YoY and by 2.4% QoQ

Efficiency

How efficient is Ironwood Pharmaceuticals business performance
The return on sales has surged by 161% year-on-year
Ironwood Pharmaceuticals's ROIC has soared by 138% YoY
Ironwood Pharmaceuticals's return on assets has decreased by 12% QoQ

Dividends

What is IRWD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IRWD.

Financial health

How did Ironwood Pharmaceuticals financials performed over time
The total assets is 13% more than the total liabilities
Ironwood Pharmaceuticals's current ratio has soared by 105% YoY and by 17% from the previous quarter
The quick ratio has surged by 98% year-on-year and by 17% since the previous quarter
IRWD's debt is up by 2.3% year-on-year and by 2.1% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.